Hombach Robert J.
SEC-identified person · CIK 1496182 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Seaport Therapeutics, Inc. SPTX | Director | filed 2026 - 2026 |
| Biomarin Pharmaceutical INC BMRN | Director | filed 2017 - 2026 |
| Schein Henry INC HSIC | Director | filed 2025 - 2026 |
| Embecta Corp. EMBC WI | Director | filed 2022 - 2026 |
| Aptinyx Inc. APTX | Director | filed 2018 - 2022 |
| Carmax INC KMX | Director | filed 2018 - 2021 |
| Baxalta Inc BXLT | Director · EVP. CFO and COO | filed 2015 - 2016 |
| Baxter International INC NYSE: BAX | Corporate Vice President & CFO | filed 2010 - 2015 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.